What changed in Merck & Co., Inc.'s latest annual report
In the year ended 31 Dec 2025, Merck & Co., Inc.'s revenue rose 1.3% to USD 65.01bn, from USD 64.17bn; net income rose 6.6% to USD 18.25bn, from USD 17.12bn; long-term debt rose 35.7% to USD 46.75bn, from USD 34.46bn.
Year ended 31 Dec 2025. Source: 10-K filed 24 Feb 2026, read it on SEC EDGAR.
USD 64.17bn to USD 65.01bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 64.17bn | 65.01bn | Up 1.3% |
| Net income | 17.12bn | 18.25bn | Up 6.6% |
| Total assets | 117.11bn | 136.87bn | Up 16.9% |
| Long-term debt | 34.46bn | 46.75bn | Up 35.7% |
| Cash and cash equivalents | 13.24bn | 14.56bn | Up 10% |
| Shareholders' equity | 46.31bn | 52.61bn | Up 13.6% |
Questions people ask
Did Merck & Co., Inc.'s revenue grow last year?
Revenue grew 1.3%, from USD 64.17bn to USD 65.01bn in the year ended 31 Dec 2025.
Is Merck & Co., Inc. profitable?
Yes. Net income was USD 18.25bn in the year ended 31 Dec 2025. The year before: USD 17.12bn.
How much cash and debt does Merck & Co., Inc. have?
At its latest year end (31 Dec 2025), Merck & Co., Inc. reported cash and cash equivalents of USD 14.56bn and long-term debt of USD 46.75bn.
Where do these numbers come from?
From Merck & Co., Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Merck & Co., Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%
- Regeneron Pharmaceuticals, Inc.Cash and cash equivalents up 25.3%